Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVX836 Influenza Vaccine Efficacy and Safety in Healthy Adults
NCT05569239Phase 2Completed
- Sponsor
- Osivax
- Start
- Sep 2025
- Primary completion
- May 2026
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
A Phase 2 trial of OVX836 in influenza, sponsored by Osivax. Started Sep 2025; status: completed.
02
Drugs
OVX836
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05569239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05569239.